Poietis mission is to provide solutions leveraging a proprietary, innovative Next-Generation Bioprinting platform and bring Tissue Engineering therapies to patients.

Poietis is a spin-off from INSERM and University of Bordeaux where Laser-Assisted Bioprinting Technology was initially developed.

On the basis of its expertise in high resolution Laser-Assisted Bioprinting, Poietis has developed the Next-Generation Bioprinting (NGB) platform. This modular platform aims to give tissue engineers and researchers greater freedom in the choice of biomaterials and hydrogels and greater versatility in their research and development.

Poietis brings to the market two bioprinters based on Next-Generation Bioprinting platform. NGB-R Bioprinter is commercialized for research applications. NGB-C Bioprinter is a clinical-grade, GMP-compliant system dedicated to clinical applications and meet the requirements of translational research and challenges of industrial manufacturing of implantable tissues.

The company has been developing physiological models for cosmetics and drug candidates screening and now markets Poieskin, the first commercially bioprinted human tissue and collaborates with the world’s leading pharmaceutical and cosmetic groups.

Leveraging the NGB platform capabilities and tissue manufacturing the skills developed in the development and production of in vitro tissue models development and production, Poietis has been developing a therapeutic pipeline of several tissue products for wound healing and other applications.